共 50 条
- [21] Zanubrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results from a Phase 1b Clinical TrialBLOOD, 2023, 142Sawalha, YazeedWelkie, Rina LiKrivenko, AnnaHess, BrianSigmund, Audrey M.Voorhees, TimothyHanel, WalterBond, David A.Reneau, John C.Epperla, NarendranathAlinari, LapoBrammer, Jonathan E.Christian, BethBaiocchi, RobertMaddocks, Kami J.
- [22] A phase III study of ibrutinib in combination with either bendamustine and rituximab (BR) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with previously treated follicular lymphoma or marginal zone lymphoma.JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)Fowler, Nathan HaleHiddemann, WolfgangLeonard, JohnLarsen, Julie S.Rose, EstherZhuang, Sen HongVermeulen, JessicaSun, StevenMentzer, LisaYeh, Tzu-MinSalles, Gilles A.
- [23] Ten-Year Follow-up of Newly Diagnosed Follicular Lymphoma Patients Treated with Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) As First-Line Therapy in JCOG0203 TrialBLOOD, 2017, 130Watanabe, TakashiTobinai, KenseiWakabayashi, MasashiMorishima, YasuoKobayashi, HirobumiKinoshita, TomohiroSuzuki, TakayoYamaguchi, MotokoAndo, KiyoshiOgura, MichinoriTaniwaki, MasafumiUike, NaokuniYoshino, TadashiNawano, ShigeruTerauchi, TakashiHotta, TomomitsuTsukasaki, Kunihiro
- [24] Phase Ib study combining ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with CD20-positive B-cell non-Hodgkin lymphoma (NHL)JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)Younes, AnasFlinn, IanBerdeja, Jesus G.Friedberg, Jonathan W.Alberti, SaraThieblemont, CatherineMorschhauser, FranckHellemans, PeterHall, BrettSmit, JohanSkee, Donnade Vries, RonaldTodorovic, MarijaKhan, ImranFourneau, NeleOki, Yasuhiro
- [25] Bortezomib maintenance after R-CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trialBRITISH JOURNAL OF HAEMATOLOGY, 2020, 190 (03) : 385 - 393Doorduijn, Jeanette K.Zijlstra, Josee M.Lugtenburg, Pieternella J.Kersten, Marie JoseeBohmer, Lara H.Minnema, Monique C.MacKenzie, Marius A.Kooij, Rien van Marwijkde Jongh, EvaSnijders, Tjeerd J. F.de Weerdt, Okkevan Gelder, MichelHoogendoorn, MelsLeys, Rineke B. L.Kibbelaar, Robby E.de Jong, DaphneChitu, Dana A.Van't Veer, Mars B.Kluin-Nelemans, Hanneke C.
- [26] Health-Related Quality of Life (HRQoL) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) in the Phase III POLARIX StudyBLOOD, 2022, 140 : 6623 - 6626Friedberg, Jonathan W.Thompson, Carrie A.Trneny, MarekMorschhauser, FranckSalles, GillesReagan, Patrick M.Hertzberg, MarkSmolewski, PiotrZhang, HuilaiThieblemont, CatherineHu, BeiFonseca, GustavoKim, Won-SeogMartelli, MaurizioMehta, AmitkumarCampinha-Bacote, AvritaYan, MarkHirata, JamieSugidono, MatthewLee, CalvinSharman, Jeff P.
- [27] A randomized, double-blind, placebo-controlled phase 3 study of ibrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) us subjects with newly diagnosed nongerminal center B-cell subtype of diffuse large B-cell lymphoma (DLBCL)JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)Younes, AnasZinzani, Pier LuigiSehn, Laurie HelenJohnson, Peter W. M.Gascoyne, Randy D.Ahmedi, TahamtanBellew, Kevin M.Verrneulen, JessicaZhuang, Sen HongSun, StevanStaudt, Louis M.Wilson, Wyndham Hopkins
- [28] A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515BLOOD, 2012, 120 (06) : 1210 - 1217Stopeck, Alison T.Unger, Joseph M.Rimsza, Lisa M.LeBlanc, MichaelFarnsworth, BrentIannone, MariaGlenn, Martha J.Fisher, Richard I.Miller, Thomas P.
- [29] DARATUMUMAB PLUS BORTEZOMIB, MELPHALAN, AND PREDNISONE (D-VMP) VERSUS BORTEZOMIB, MELPHALAN, AND PREDNISONE (VMP) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS (PTS) INELIGIBLE FOR TRANSPLANT: A PHASE 3 RANDOMIZED STUDY (ALCYONE)HAEMATOLOGICA, 2018, 103 : 22 - 22Mateos, M., VDimopoulos, M. A.Cavo, M.Suzuki, K.Jakubowiak, A.Knop, S.Doyen, C.Lucio, P.Nagy, Z.Kaplan, P.PouCook, M.Grosicki, S.Crepaldi, A.Liberati, A. M.Campbell, P.Shelekhova, T.Yoon, S. S.Iosava, G.Fujisaki, T.Garg, M.Chiu, C.Wang, J.Carson, R.Crist, W.Deraedt, W.Nguyen, H.Qi, M.San-Miguel, J.
- [30] Phase 3 Randomized Study of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Ineligible for Transplant (ALCYONE)BLOOD, 2017, 130Mateos, Maria-VictoriaDimopoulos, Meletios A.Cavo, MicheleSuzuki, KenshiJakubowiak, Andrzej J.Knop, StefanDoyen, ChantalLucio, PauloNagy, ZsoltKaplan, PolinaPour, LudekCook, MarkGrosicki, SebastianCrepaldi, Andre H.Liberati, Anna MarinaCampbell, PhilipShelekhova, TatianaYoon, Sung-SooIosava, GenadiFujisaki, TomoakiGarg, MamtaChiu, ChristopherWang, JianpingCarson, RobinCrist, WendyDeraedt, WilliamNguyen, MarieQi, MingSan-Miguel, Jesus F.